NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced after the close of the market on Thursday a commercialization deal with Lamprogen.
Lamprogen, a University of Washington spinout, has granted Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles. The particles can be used in a broad array of assays and research applications including flow cytometry, Bio-Rad said, adding it expects to commercialize the products in 2013.
The deal also grants Bio-Rad access to future technologies developed by Lamprogen.
Financial and other terms were not disclosed.
"Combining Lamprogen's unique fluorescent particles with antibodies or other biomolecules will enable our customers to create single and multiplex assays with greater detection capabilities," Brad Crutchfield, Bio-Rad executive vice president and president of the Life Science Group, said in a statement.